ReNeuron Group plc ReNeuron's lead cell line shows further potential (4082E)
18 October 2018 - 5:01PM
UK Regulatory
TIDMRENE
RNS Number : 4082E
ReNeuron Group plc
18 October 2018
AIM: RENE 18 October 2018
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron's lead cell line shows further potential
New data shows ReNeuron's lead CTX cell therapy candidate can
be
re-programmed into a pluripotent state and differentiated into
other cell types
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is pleased to announce that
new data relating to its CTX stem cell platform will be presented
today at the 26(th) Annual Congress of the European Society of Gene
and Cell Therapy (ESGCT), a leading scientific conference taking
place this week in Lausanne, Switzerland.
Dr Steve Pells, Principal Investigator at ReNeuron, will present
data demonstrating for the first time that the Company's
proprietary, conditionally immortalised, human neural stem cell
line (CTX), currently undergoing clinical evaluation for the
treatment of stroke disability, can be successfully re-programmed
to a pluripotent state (that is, to an embryonic stem cell-like
state enabling differentiation into any cell type). The poster
presentation will also show that CTX-iPSCs (induced pluripotent
stem cells) can be successfully differentiated along a different
lineage from the original cell line (specifically, a mesenchymal
stem cell line), and critically that ReNeuron's immortalisation
technology remains functional in the reprogrammed pluripotent
cells.
These results, albeit early stage, are particularly encouraging
as they demonstrate that CTX, a well-characterised, clinical-grade
neural stem cell line, could be used to produce new conditionally
immortalised allogeneic (i.e. non-donor-specific) cell lines from
any of the three germ layers: ectoderm, mesoderm and endoderm.
ReNeuron will now look to develop further new allogeneic cell
lines, including NK and T-cells (the cells that can be modified to
attack cancer cells), as potential therapeutic agents for licensing
to third parties.
Further information about this conference may be found at
http://www.isscr.org/meetings-events/international-symposia/lausanne-2018.
Commenting on the data, Dr Randolph Corteling, Head of Research
at ReNeuron, said:
"The data we are presenting at the ESGCT Annual Congress
represents a significant advance in the use of cell re-programming
to generate new allogeneic cell lines as potential therapeutic
candidates. Importantly, the possibility of generating an
allogeneic source of haematopoietic stem cells from our
clinical-grade CTX cell line offers the prospect of a potential
non-patient-specific alternative to those cancer immunotherapies in
development that currently rely on the use of the patient's own
T-cells."
ENDS
Enquiries:
+44 (0)20 3819
ReNeuron 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
+44 (0) 20 7466
Buchanan 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited
Jonathan Senior, Stewart Wallace, Ben +44 (0) 20 7710
Maddison (NOMAD and Joint Broker) 7600
N+1 Singer Advisory LLP +44 (0) 20 7496
Mark Taylor (Joint Broker) 3000
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This announcement contains forward-looking statements with
respect to the financial condition, results of operations and
business achievements/performance of ReNeuron and certain of the
plans and objectives of management of ReNeuron with respect
thereto. These statements may generally, but not always, be
identified by the use of words such as "should", "expects",
"estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain
third parties relating to their estimates regarding the growth of
markets and demand for products. By their nature, forward-looking
statements involve risk and uncertainty because they reflect
ReNeuron's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of factors
could cause ReNeuron's actual financial condition, results of
operations and business achievements/performance to differ
materially from the estimates made or implied in such
forward-looking statements and, accordingly, reliance should not be
placed on such statements.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDGGGWUUUPRPGM
(END) Dow Jones Newswires
October 18, 2018 02:01 ET (06:01 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024